-
Product Insights
Papillary Renal Cell Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Papillary Renal Cell Carcinoma - Drugs In Development, 2023’, provides an overview of the Papillary Renal Cell Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Papillary Renal Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Squamous Non-Small Cell Lung Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Squamous Non-Small Cell Lung Carcinoma - Drugs In Development, 2023’, provides an overview of the Squamous Non-Small Cell Lung Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Squamous Non-Small Cell Lung Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Lung Adenocarcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Lung Adenocarcinoma - Drugs In Development, 2023’, provides an overview of the Lung Adenocarcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lung Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Non-Small Cell Lung Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Non-Small Cell Lung Carcinoma - Drugs In Development, 2023’, provides an overview of the Non-Small Cell Lung Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AU-314 in Metastatic Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AU-314 in Metastatic Colorectal Cancer Drug Details: AU-314 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab Biosimilar in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab Biosimilar in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab Biosimilar in Metastatic Melanoma Drug Details: Pembrolizumab (Pembroria) is...
-
Product Insights
NewNet Present Value Model: Solid Biosciences Inc’s SGT-001
Empower your strategies with our Net Present Value Model: Solid Biosciences Inc's SGT-001 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – pVAX-hSlo in Urinary Incontinence
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - pVAX-hSlo in Urinary Incontinence report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PVAX-hSlo in Urinary Incontinence Drug Details: pVAX-hSlo (hmaxi-K) gene transfer therapy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ZD-100 in Resistant Hypertension
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ZD-100 in Resistant HypertensionDrug Details:ZD-100 is under development for the treatment of resistant hypertension. The drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Equine Encephalitis Vaccine in Western Equine Encephalitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Equine Encephalitis Vaccine in Western Equine Encephalitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Equine Encephalitis Vaccine in Western Equine EncephalitisDrug Details:Vaccine (MVA-BN WEV)...